Multivalent & multifunctional ligands to β-amyloid

Current Pharmaceutical Design

Volumn 15, Issue 6, 2009, Pages 637-658

  Kim, Young Soo ^a   Lee, Ji Hoon ^a   Ryu, Jiyeon ^a   Kim, Dong Jin ^a  

^a Korea Institute of Science and Technology   (South Korea)

Author keywords

amyloid; A ; AD drug; Alzheimer's disease; Early diagnosis; Imaging probe; Ligand; Multifunction; Multivalent

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; ANTIOXIDANT; BAPINEUZUMAB; BENZOTHIAZOLE DERIVATIVE; BISPYRIDINIUM DERIVATIVE; CHOLINESTERASE INHIBITOR; CONGO RED; DENDRIMER; DONEPEZIL; FERULIC ACID; GALANTAMINE; HOMOTAURINE; MEMANTINE; METAL CHELATE; N METHYL N BENZYLAMINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PENTETIC ACID; PHENAZOPYRIDINE; PLACEBO; POLYPHENOL DERIVATIVE; QUINONE DERIVATIVE; RIVASTIGMINE; SKF 64346; TACRINE; THIOFLAVINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN; XH 1; LIGAND;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CHELATION; CLINICAL TRIAL; DEMENTIA; DRUG BINDING SITE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG TRANSFORMATION; EARLY DIAGNOSIS; HUMAN; LIGAND BINDING; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PHARMACOLOGICAL BLOCKING; PHARMACOPHORE; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; BRAIN; DRUG DELIVERY SYSTEM; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROTEIN BINDING;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIGANDS; OXIDATIVE STRESS; PROTEIN BINDING;

EID: 65549161050     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787315648     Document Type: Review

References (191)

1. Maslow K. 2008 Alzheimer's disease facts and figures. Alzheimer's Dementia 2008; 4: 110-33.
2. Alzheimer A. A contribution concerning the pathological anatomy of mental disturbances in old age, 1899. Alzheimer Dis Assoc Disord 1991; 5: 69-70.
3. Hardy JA, Higgins GA. Alzheimer's disease: The amyloid cascade hypothesis. Science 1992; 256: 184-5.
4. Lee RK, Wurtman RJ, Cox AJ, Nitsch RM. Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors. Proc Natl Acad Sci USA 1995; 92: 8083-7.
5. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 486-9.
6. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, et al. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 1996; 271: 4077-81
7. Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ, et al. Morphology and toxicity of A beta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem 1996; 271: 20631-5.
8. Blanchard BJ, Konopka G, Russell M, Ingram VM. Mechanism and prevention of neurotoxicity caused by beta-amyloid peptides: Relation to Alzheimer's disease. Brain Res 1997; 776: 40-50.
9. Shoji M, Kawarabayashi T, Sato M, Sasaki A, Saido TC, Matsubara E, et al. Age-related amyloid beta protein accumulation induces cellular death and macrophage activation in transgenic mice. J Pathol 2000; 191: 93-101.
10. Selkoe DJ, Schenk D. Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003; 43: 545-84.
11. Hartmann T, Bieger SC, Bruhl B, Tienari PJ, Ida N, Allsop D, et al. Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. Nat Med 1997; 3: 1016-20.
12. Pitschke M, Prior R, Haupt M, Riesner D. Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat Med 1998; 4: 832-4.
13. Klein WL, Stine WB, Jr., Teplow DB. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 2004; 25: 569-80.
14. Stine WB, Jr., Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem 2003; 278: 11612-22.
15. Balakrishnan R, Parthasarathy R, Sulkowski E. Alzheimer's beta-amyloid peptide: Affinity for metal chelates. J Pept Res 1998; 51: 91-5.
16. Butterfield DA, Kanski J. Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer's amyloid beta-peptide 1-42. Peptides 2002; 23: 1299-309.
17. Liu ST, Howlett G, Barrow CJ. Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the A beta peptide of Alzheimer's disease. Biochemistry 1999; 38: 9373-8.
18. Schoneich C, Pogocki D, Hug GL, Bobrowski K. Free radical reactions of methionine in peptides: Mechanisms relevant to beta-amyloid oxidation and Alzheimer's disease. J Am Chem Soc 2003; 125: 13700-13.
19. Klunk WE, Debnath ML, Pettegrew JW. Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. Neurobiol Aging 1994; 15: 691-8.
20. Skovronsky DM, Zhang B, Kung MP, Kung HF, Trojanowski JQ, Lee VM. In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2000; 97: 7609-14.
21. Agdeppa ED, Kepe V, Liu J, Small GW, Huang SC, Petric A, et al. 2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): Novel diagnostic and therapeutic tools in Alzheimer's disease. Mol Imaging Biol 2003; 5: 404-17.
22. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-19.
23. Mathis CA, Bacskai BJ, Kajdasz ST, McLellan ME, Frosch MP, Hyman BT, et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 2002; 12: 295-8.
24. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
25. Choi DS, Wang D, Yu GQ, Zhu G, Kharazia VN, Paredes JP, et al. PKCepsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice. Proc Natl Acad Sci USA 2006; 103: 8215-20.
26. Hamaguchi T, Ono K, Yamada M. Anti-amyloidogenic therapies: Strategies for prevention and treatment of Alzheimer's disease. Cell Mol Life Sci 2006; 63: 1538-52.
27. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-7.
28. Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, et al. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 2007; 28: 537-47.
29. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001; 30: 665-76.
30. Melnikova I. Therapies for Alzheimer's disease. Nat Rev Drug Discov 2007; 6: 341-2.
31. Mammen M, Choi SK, Whitesides GM. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed 1998; 37: 2755-94.
32. Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs? Curr Opin Struct Biol 2006; 16: 127-36.
33. Morphy R, Rankovic Z. The physicochemical challenges of designing multiple ligands. J Med Chem 2006; 49: 4961-70.
34. Kung HF, Lee CW, Zhuang ZP, Kung MP, Hou C, Plossl K. Novel stilbenes as probes for amyloid plaques. J Am Chem Soc 2001; 123: 12740-1.
35. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 2005; 48: 6523-43.
36. Klunk WE, Pettegrew JW, Abraham DJ. Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J Histochem Cytochem 1989; 37: 1273-81.
37. LeVine H, 3rd. Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 1999; 309: 274-84.
38. Klunk WE, Debnath ML, Pettegrew JW. Chrysamine-G binding to Alzheimer and control brain: Autopsy study of a new amyloid probe. Neurobiol Aging 1995; 16: 541-8.
39. Stokes MI, Trickey RJ. Screening for neurofibrillary tangles and argyrophilic plaques with Congo Red and polarized light. J Clin Pathol 1973; 26: 241-2.
40. Salminen T, Pulli A, Taskinen J. Relationship between immobilised artificial membrane chromatographic retention and the brain penetration of structurally diverse drugs. J Pharm Biomed Anal 1997; 15: 469-77
41. Lee CW, Zhuang ZP, Kung MP, Plossl K, Skovronsky D, Gur T, et al. Isomerization of (Z,Z) to (E,E)1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene in strong base: Probes for amyloid plaques in the brain. J Med Chem 2001; 44: 2270-5.
42. Kung MP, Hou C, Zhuang ZP, Skovronsky DM, Zhang B, Gur TL, et al. Radioiodinated styrylbenzene derivatives as potential SPECT imaging agents for amyloid plaque detection in Alzheimer's disease. J Mol Neurosci 2002; 19: 7-10.
43. Zhuang ZP, Kung MP, Hou C, Plossl K, Skovronsky D, Gur TL, et al. IBOX(2-(4′-dimethylaminophenyl)-6-iodobenzoxazole): A ligand for imaging amyloid plaques in the brain. Nucl Med Biol 2001; 28: 887-94
44. Ono M, Wilson A, Nobrega J, Westaway D, Verhoeff P, Zhuang ZP, et al. 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. Nucl Med Biol 2003; 30: 565-71.
45. Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, et al. In vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 2004; 12: 584-95.
46. Kung MP, Hou C, Zhuang ZP, Zhang B, Skovronsky D, Trojanowski JQ, et al. IMPY: An improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. Brain Res 2002; 956: 202-10.
47. Mathis CA, Wang Y, Klunk WE. Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Des 2004; 10: 1469-92.
48. Lee JH, Byeon SR, Lim SJ, Oh SJ, Moon DH, Yoo KH, et al. Synthesis and evaluation of stilbenylbenzoxazole and stilbenylbenzothiazole derivatives for detecting beta-amyloid fibrils. Bioorg Med Chem Lett 2008; 18: 1534-7.
49. Lee HJ, Lim SJ, Oh SJ, Moon DH, Kim DJ, Tae J, et al. Isoindol-1,3-dione and isoindol-1-one derivatives with high binding affinity to beta-amyloid fibrils. Bioorg Med Chem Lett 2008; 18: 1628-31.
50. Sullivan M. Tramiprosate falls short in phase III Alzheimer's trial. Clin Psychiatry News 2007; 35: 27.
51. Black SE. S3-02-02: Flurizan. Alzheimer's Dementia 2007; 3: S199.
52. Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD, Luehrs DC, et al. Amyloid-{beta} peptide remnants in AN-1792-immunized Alzheimer's disease patients: A biochemical analysis. Am J Pathol 2006; 169: 1048-63.
53. Nakagami Y, Nishimura S, Murasugi T, Kaneko I, Meguro M, Marumoto S, et al. A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro. Br J Pharmacol 2002; 137: 676-82.
54. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy. Nat Med 1998; 4: 822-6.
55. Tjernberg LO, Naslund J, Lindqvist F, Johansson J, Karlstrom AR, Thyberg J, et al. Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem 1996; 271: 8545-8.
56. Soto C, Kindy MS, Baumann M, Frangione B. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun 1996; 226: 672-80.
57. Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides. J Mol Biol 1992; 228: 460-73.
58. Tjernberg LO, Naslund J, Thyberg J, Gandy SE, Terenius L, Nordstedt C. Generation of Alzheimer amyloid beta peptide through nonspecific proteolysis. J Biol Chem 1997; 272: 1870-5.
59. Watanabe K, Nakamura K, Akikusa S, Okada T, Kodaka M, Konakahara T, et al. Inhibitors of fibril formation and cytotoxicity of beta-amyloid peptide composed of KLVFF recognition element and flexible hydrophilic disrupting element. Biochem Biophys Res Commun 2002; 290: 121-4.
60. Chacon MA, Barria MI, Soto C, Inestrosa NC. Beta-sheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits. Mol Psychiatry 2004; 9: 953-61.
61. Chafekar SM, Malda H, Merkx M, Meijer EW, Viertl D, Lashuel HA, et al. Branched KLVFF tetramers strongly potentiate inhibition of beta-amyloid aggregation. ChemBioChem 2007; 8: 1857-64.
62. Helms B, Meijer EW. Chemistry. Dendrimers at work. Science 2006; 313: 929-30.
63. van Baal I, Malda H, Synowsky SA, van Dongen JL, Hackeng TM, Merkx M, et al. Multivalent peptide and protein dendrimers using native chemical ligation. Angew Chem Int Ed 2005; 44: 5052-7.
64. Zhang G, Leibowitz MJ, Sinko PJ, Stein S. Multiple-peptide conjugates for binding beta-amyloid plaques of Alzheimer's disease. Bioconjug Chem 2003; 14: 86-92.
65. Suemoto T, Okamura N, Shiomitsu T, Suzuki M, Shimadzu H, Akatsu H, et al. In vivo labeling of amyloid with BF-108. Neurosci Res 2004; 48: 65-74.
66. Dolphin GT, Chierici S, Ouberai M, Dumy P, Garcia J. A multimeric quinacrine conjugate as a potential inhibitor of Alzheimer's beta-amyloid fibril formation. ChemBioChem 2008; 9: 952-63.
67. May BC, Fafarman AT, Hong SB, Rogers M, Deady LW, Prusiner SB, et al. Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc Natl Acad Sci USA 2003; 100: 3416-21.
68. Dolphin GT, Dumy P, Garcia J. Control of amyloid beta-peptide protofibril formation by a designed template assembly. Angew Chem Int Ed 2006; 45: 2699-702.
69. Mutter M. Nature's rules and chemist's tools: A way for creating novel proteins. Trends Biochem Sci 1988; 13: 260-5.
70. Jarrett JT, Lansbury PT, Jr. Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993; 73: 1055-8.
71. Lomakin A, Teplow DB, Kirschner DA, Benedek GB. Kinetic theory of fibrillogenesis of amyloid beta-protein. Proc Natl Acad Sci USA 1997; 94: 7942-7.
72. Naiki H, Gejyo F. Kinetic analysis of amyloid fibril formation. Methods Enzymol 1999; 309: 305-18.
73. Naiki H, Nakakuki K. First-order kinetic model of Alzheimer's beta-amyloid fibril extension in vitro. Lab Invest 1996; 74: 374-83.
74. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002; 295: 2264-7.
75. Yan JJ, Cho JY, Kim HS, Kim KL, Jung JS, Huh SO, et al. Protection against beta-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br J Pharmacol 2001; 133: 89-96.
76. Lee KH, Shin BH, Shin KJ, Kim DJ, Yu J. A hybrid molecule that prohibits amyloid fibrils and alleviates neuronal toxicity induced by beta-amyloid (1-42). Biochem Biophys Res Commun 2005; 328: 816-23.
77. Byeon SR, Lee JH, Sohn JH, Kim DC, Shin KJ, Yoo KH, et al. Bis-styrylpyridine and bis-styrylbenzene derivatives as inhibitors for Abeta fibril formation. Bioorg Med Chem Lett 2007; 17: 1466-70.
78. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci USA 2003; 100: 330-5.
79. Byeon SR, Jin YJ, Lim SJ, Lee JH, Yoo KH, Shin KJ, et al. Ferulic acid and benzothiazole dimer derivatives with high binding affinity to beta-amyloid fibrils. Bioorg Med Chem Lett 2007; 17: 4022-5.
80. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003; 46: 2740-54.
81. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 486-9.
82. Soreghan B, Kosmoski J, Glabe C. Surfactant properties of Alzheimer's A beta peptides and the mechanism of amyloid aggregation. J Biol Chem 1994; 269: 28551-4.
83. Garzon-Rodriguez W, Vega A, Sepulveda-Becerra M, Milton S, Johnson DA, Yatsimirsky AK, et al. A conformation change in the carboxyl terminus of Alzheimer's Abeta (1-40) accompanies the transition from dimer to fibril as revealed by fluorescence quenching analysis. J Biol Chem 2000; 275: 22645-9.
84. Stains CI, Mondal K, Ghosh I. Molecules that target beta-amyloid. ChemMedChem 2007; 2: 1674-92.
85. Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, et al. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 2008; 51: 347-72.
86. Youdim MB, Amit T, Bar-Am O, Weinreb O, Yogev-Falach M. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotectiveneurorescue drugs; ladostigil. Neurotox Res 2006; 10: 181-92.
87. Ramanathan S, Qiu B, Pooyan S, Zhang G, Stein S, Leibowitz MJ, et al. Targeted PEG-based bioconjugates enhance the cellular uptake and transport of a HIV-1 TAT nonapeptide. J Control Release 2001; 77: 199-212.
88. DeLano WL, Ultsch MH, de Vos AM, Wells JA. Convergent solutions to binding at a protein-protein interface. Science 2000; 287: 1279-83.
89. Veselovsky AV, Ivanov YD, Ivanov AS, Archakov AI, Lewi P, Janssen P. Protein-protein interactions: Mechanisms and modification by drugs. J Mol Recognit 2002; 15: 405-22.
90. Bose M, Gestwicki JE, Devasthali V, Crabtree GR, Graef IA. 'Nature-inspired' drug-protein complexes as inhibitors of Abeta aggregation. Biochem Soc Trans 2005; 33: 543-7.
91. Gestwicki JE, Crabtree GR, Graef IA. Harnessing chaperones to generate small-molecule inhibitors of amyloid beta aggregation. Science 2004; 306: 865-9.
92. Holt DA, Luengo JI, Yamashita DS, Oh HJ, Konialian AL, Yen HK, et al. Design, synthesis, and kinetic evaluation of high-affinity FKBP ligands and the X-ray crystal structures of their complexes with FKBP12. J Am Chem Soc 1993; 115: 9925-38.
93. Westermark GT, Johnson KH, Westermark P. Staining methods for identification of amyloid in tissue. Methods Enzymol 1999; 309: 3-25
94. Lee VM. Amyloid binding ligands as Alzheimer's disease therapies. Neurobiol Aging 2002; 23: 1039-42.
95. Findeis MA. Approaches to discovery and characterization of inhibitors of amyloid beta-peptide polymerization. Biochim Biophys Acta 2000; 1502: 76-84.
96. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, et al. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 1998; 273: 12817-26.
97. Bush AI, Pettingell WH, Multhaup G, d Paradis M, Vonsattel JP, Gusella JF, et al. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 1994; 265: 1464-7.
98. Huang X, Atwood CS, Moir RD, Hartshorn MA, Vonsattel JP, Tanzi RE, et al. Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors. J Biol Chem 1997; 272: 26464-70.
99. Boldron C, Van der Auwera I, Deraeve C, Gornitzka H, Wera S, Pitie M, et al. Preparation of cyclo-phen-type ligands: Chelators of metal ions as potential therapeutic agents in the treatment of neurodegenerative diseases. ChemBioChem 2005; 6: 1976-80.
100. Cherny RA, Legg JT, McLean CA, Fairlie DP, Huang X, Atwood CS, et al. Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem 1999; 274: 23223-8.
101. Cui Z, Lockman PR, Atwood CS, Hsu CH, Gupte A, Allen DD, et al. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur J Pharm Biopharm 2005; 59: 263-72.
102. Regland B, Lehmann W, Abedini I, Blennow K, Jonsson M, Karlsson I, et al. Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord 2001; 12: 408-14.
103. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch Neurol 2003; 60: 1685-91.
104. Huang X, Moir RD, Tanzi RE, Bush AI, Rogers JT. Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Ann N Y Acad Sci 2004; 1012: 153-63.
105. Dedeoglu A, Cormier K, Payton S, Tseitlin KA, Kremsky JN, Lai L, et al. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. Exp Gerontol 2004; 39: 1641-9
106. Suh J, Yoo SH, Kim MG, Jeong K, Ahn JY, Kim MS, et al. Cleavage agents for soluble oligomers of amyloid beta peptides. Angew Chem Int Ed 2007; 46: 7064-7.
107. Buckingham DA, Keene FR, Sargeson AM. Facile intramolecular hydrolysis of dipeptides and glycinamide. J Am Chem Soc 1974; 96: 4981-3.
108. Chae PS, Kim MS, Jeung CS, Lee SD, Park H, Lee S, et al. Peptide-cleaving catalyst selective for peptide deformylase. J Am Chem Soc 2005; 127: 2396-7.
109. Jeon JW, Son SJ, Yoo CE, Hong IS, Song JB, Suh J. Protein-cleaving catalyst selective for protein substrate. Org Lett 2002; 4: 4155-8.
110. Jeon JW, Son SJ, Yoo CE, Hong IS, Suh J. Toward protein-cleaving catalytic drugs: Artificial protease selective for myoglobin. Bioorg Med Chem 2003; 11: 2901-10.
111. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999; 155: 853-62.
112. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403.
113. Bartus RT, Dean RL, 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-14.
114. Bowen DM, Francis PT, Pangalos MN, Stephens PH, Procter AW. Treatment strategies for Alzheimer's disease. Lancet 1992; 339: 132-3.
115. Camps P, Muñoz-Torrero D. Cholinergic drugs in pharmacotherapy of Alzheimer's disease. Mini Rev Med Chem 2002; 2: 11-25.
116. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 1994; 271: 985-91.
117. Jann MW. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 2000; 20: 1-12.
118. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158: 1021-31.
119. Wilcock GK, Lilienfeld S, Gaens E, Addington D, Ancill R, Bergman H, et al. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. Galantamine International-1 Study Group. Br Med J 2000; 321: 1445-9.
120. Ibach B, Haen E. Acetylcholinesterase inhibition in Alzheimer's Disease. Curr Pharm Des 2004; 10: 231-51.
121. Bartolini M, Bertucci C, Cavrini V, Andrisano V. beta-Amyloid aggregation induced by human acetylcholinesterase: Inhibition studies. Biochem Pharmacol 2003; 65: 407-16.
122. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme. Neuron 1996; 16: 881-91.
123. Alvarez A, Opazo C, Alarcon R, Garrido J, Inestrosa NC. Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. J Mol Biol 1997; 272: 348-61.
124. Muñoz FJ, Inestrosa NC. Neurotoxicity of acetylcholinesterase amyloid beta-peptide aggregates is dependent on the type of Abeta peptide and the AChE concentration present in the complexes. FEBS Lett 1999; 450: 205-9.
125. De Ferrari GV, Canales MA, Shin I, Weiner LM, Silman I, Inestrosa NC. A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry 2001; 40: 10447-57.
126. Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 2003; 4: 131-8.
127. Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: Correlation with cognitive benefit. J Neural Transm 2002; 109: 1053-65.
128. Greig NH, Utsuki T, Yu Q, Zhu X, Holloway HW, Perry T, et al. A new therapeutic target in Alzheimer's disease treatment: Attention to butyrylcholinesterase. Curr Med Res Opin 2001; 17: 159-65.
129. Diamant S, Podoly E, Friedler A, Ligumsky H, Livnah O, Soreq H. Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci USA 2006; 103: 8628-33.
130. Rizzo S, Riviere C, Piazzi L, Bisi A, Gobbi S, Bartolini M, et al. Benzofuran-based hybrid compounds for the inhibition of cholinesterase activity, beta amyloid aggregation, and abeta neurotoxicity. J Med Chem 2008; 51: 2883-6.
131. Howlett DR, Perry AE, Godfrey F, Swatton JE, Jennings KH, Spitzfaden C, et al. Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans. Biochem J 1999; 340: 283-9.
132. Belluti F, Rampa A, Piazzi L, Bisi A, Gobbi S, Bartolini M, et al. Cholinesterase inhibitors: Xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation. J Med Chem 2005; 48: 4444-56.
133. Rampa A, Piazzi L, Belluti F, Gobbi S, Bisi A, Bartolini M, et al. Acetylcholinesterase inhibitors: SAR and kinetic studies on omega-N-methyl-N-(3-alkylcarbamoyloxyphenyl)methylaminoalkoxyaryl derivatives. J Med Chem 2001; 44: 3810-20.
134. Riviere C, Richard T, Quentin L, Krisa S, Merillon JM, Monti JP. Inhibitory activity of stilbenes on Alzheimer's beta-amyloid fibrils in vitro. Bioorg Med Chem 2007; 15: 1160-7.
135. Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res 2004; 75: 742-50.
136. Kapkova P, Alptuzun V, Frey P, Erciyas E, Holzgrabe U. Search for dual function inhibitors for Alzheimer's disease: Synthesis and biological activity of acetylcholinesterase inhibitors of pyridinium-type and their Abeta fibril formation inhibition capacity. Bioorg Med Chem 2006; 14: 472-8.
137. Kapkova P, Stiefl N, Surig U, Engels B, Baumann K, Holzgrabe U. Synthesis, biological activity, and docking studies of new acetylcholinesterase inhibitors of the bispyridinium type. Arch Pharm 2003; 336: 523-40.
138. Frank B, Gupta S. A review of antioxidants and Alzheimer's disease. Ann Clin Psychiatry 2005; 17: 269-86.
139. Butterfield DA, Drake J, Pocernich C, Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: Central role for amyloid beta-peptide. Trends Mol Med 2001; 7: 548-54.
140. Tabner BJ, Turnbull S, El-Agnaf O, Allsop D. Production of reactive oxygen species from aggregating proteins implicated in Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. Curr Top Med Chem 2001; 1: 507-17.
141. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radical Biol Med 1997; 23: 134-47.
142. Behl C. Alzheimer's disease and oxidative stress: Implications for novel therapeutic approaches. Prog Neurobiol 1999; 57: 301-23.
143. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 1994; 77: 817-27.
144. Bush AI, Masters CL, Tanzi RE. Copper, beta-amyloid, and Alzheimer's disease: Tapping a sensitive connection. Proc Natl Acad Sci USA 2003; 100: 11193-4.
145. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997; 94: 9866-8.
146. Doraiswamy PM, Finefrock AE. Metals in our minds: Therapeutic implications for neurodegenerative disorders. Lancet Neurol 2004; 3: 431-4.
147. Gaggelli E, Kozlowski H, Valensin D, Valensin G. Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Chem Rev 2006; 106: 1995-2044.
148. Ono K, Hamaguchi T, Naiki H, Yamada M. Anti-amyloidogenic effects of antioxidants: Implications for the prevention and therapeutics of Alzheimer's disease. Biochim Biophys Acta 2006; 1762: 575-86.
149. Bastianetto S, Zheng WH, Quirion R. Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons. Br J Pharmacol 2000; 131: 711-20.
150. Choi YT, Jung CH, Lee SR, Bae JH, Baek WK, Suh MH, et al. The green tea polyphenol (-)-epigallocatechin gallate attenuates beta-amyloid-induced neurotoxicity in cultured hippocampal neurons. Life Sci 2001; 70: 603-14.
151. Levites Y, Weinreb O, Maor G, Youdim MB, Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 2001; 78: 1073-82.
152. Inanami O, Watanabe Y, Syuto B, Nakano M, Tsuji M, Kuwabara M. Oral administration of (-)catechin protects against ischemia-reperfusion-induced neuronal death in the gerbil. Free Radical Res 1998; 29: 359-65.
153. Shutenko Z, Henry Y, Pinard E, Seylaz J, Potier P, Berthet F, et al. Influence of the antioxidant quercetin in vivo on the level of nitric oxide determined by electron paramagnetic resonance in rat brain during global ischemia and reperfusion. Biochem Pharmacol 1999; 57: 199-208.
154. Virgili M, Contestabile A. Partial neuroprotection of in vivo excitotoxic brain damage by chronic administration of the red wine antioxidant agent, trans-resveratrol in rats. Neurosci Lett 2000; 281: 123-6.
155. Naiki H, Hasegawa K, Yamaguchi I, Nakamura H, Gejyo F, Nakakuki K. Apolipoprotein E and antioxidants have different mechanisms of inhibiting Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry 1998; 37: 17882-9.
156. Ono K, Hasegawa K, Naiki H, Yamada M. Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's beta-amyloid fibrils in vitro. Biochim Biophys Acta 2004; 1690: 193-202.
157. Ono K, Hasegawa K, Yoshiike Y, Takashima A, Yamada M, Naiki H. Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's beta-amyloid fibrils in vitro. J Neurochem 2002; 81: 434-40.
158. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: Implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem 2003; 87: 172-81.
159. Yokozawa T, Chen CP, Dong E, Tanaka T, Nonaka GI, Nishioka I. Study on the inhibitory effect of tannins and flavonoids against the 1,1-diphenyl-2 picrylhydrazyl radical. Biochem Pharmacol 1998; 56: 213-22.
160. Okuda T, Kimura Y, Yoshida T, Hatano T, Okuda H, Arichi S. Studies on the activities of tannins and related compounds from medicinal plants and drugs. I. Inhibitory effects on lipid peroxidation in mitochondria and microsomes of liver. Chem Pharm Bull 1983; 31: 1625-31.
161. Krinsky NI. Antioxidant functions of carotenoids. Free Radical Biol Med 1989; 7: 617-35.
162. Tesoriere L, Ciaccio M, Bongiorno A, Riccio A, Pintaudi AM, Livrea MA. Antioxidant activity of all-trans-retinol in homogeneous solution and in phosphatidylcholine liposomes. Arch Biochem Biophys 1993; 307: 217-23.
163. Yallampalli S, Micci MA, Taglialatela G. Ascorbic acid prevents beta-amyloid-induced intracellular calcium increase and cell death in PC12 cells. Neurosci Lett 1998; 251: 105-8.
164. Behl C, Davis J, Cole GM, Schubert D. Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem Biophys Res Commun 1992; 186: 944-50.
165. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro. Exp Neurol 2004; 189: 380-92.
166. Bolognesi ML, Minarini A, Budriesi R, Cacciaguerra S, Chiarini A, Spampinato S, et al. Universal template approach to drug design: polyamines as selective muscarinic receptor antagonists. J Med Chem 1998; 41: 4150-60.
167. Cavalli A, Bolognesi ML, Capsoni S, Andrisano V, Bartolini M, Margotti E, et al. A small molecule targeting the multifactorial nature of Alzheimer's disease. Angew Chem Int Ed Engl 2007; 46: 3689-92.
168. Bolognesi ML, Banzi R, Bartolini M, Cavalli A, Tarozzi A, Andrisano V, et al. Novel class of quinone-bearing polyamines as multitarget-directed ligands to combat Alzheimer's disease. J Med Chem 2007; 50: 4882-97.
169. Rice-Evans C, Miller NJ. Total antioxidant status in plasma and body fluids. Methods Enzymol 1994; 234: 279-93.
170. Mordente A, Martorana GE, Minotti G, Giardina B. Antioxidant properties of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebenone). Chem Res Toxicol 1998; 11: 54-63.
171. Capsoni S, Cattaneo A. On the molecular basis linking Nerve Growth Factor (NGF) to Alzheimer's disease. Cell Mol Neurobiol 2006; 26: 619-33.
172. Capsoni S, Ugolini G, Comparini A, Ruberti F, Berardi N, Cattaneo A. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc Natl Acad Sci USA 2000; 97: 6826-31.
173. Halliday G, Robinson SR, Shepherd C, Kril J. Alzheimer's disease and inflammation: A review of cellular and therapeutic mechanisms. Clin Exp Pharmacol Physiol 2000; 27: 1-8.
174. McGeer PL, McGeer EG. Inflammation of the brain in Alzheimer's disease:
175. Bullock R. New drugs for Alzheimer's disease and other dementias. Br J Psychiatry 2002; 180: 135-9.
176. Hull M, Fiebich BL, Schumann G, Lieb K, Bauer J. Anti-inflammatory substances - a new therapeutic option in Alzheimer's disease. Drug Discov Today 1999; 4: 275-82.
177. Pasinetti GM. Cyclooxygenase and Alzheimer's disease: Implications for preventive initiatives to slow the progression of clinical dementia. Arch Gerontol Geriatr 2001; 33: 13-28.
178. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 1996; 47: 425-32.
179. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997; 48: 626-32.
180. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 2000; 20: 5709-14.
181. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA 2003; 289: 2819-26.
182. Liang X, Wang Q, Hand T, Wu L, Breyer RM, Montine TJ, et al. Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J Neurosci 2005; 25: 10180-7.
183. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 2000; 54: 588-93.
184. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999; 53: 197-201.
185. Thomas T, Nadackal TG, Thomas K. Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation. Neuroreport 2001; 12: 3263-7.
186. Agdeppa ED, Kepe V, Petri A, Satyamurthy N, Liu J, Huang SC, et al. In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)]Ffluoroethyl) (methyl)amino-2-naphthylethylidene)malono nitrile. Neuroscience 2003; 117: 723-30.
187. Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci 2001; 21: RC189.
188. Lynch L. Pipeline and commercial insight: Alzheimer's disease - beta treatments on the horizon. Research report: Datamonitor; 2005. Report No.: DMHC2121.
189. Deane R, Sagare A, Zlokovic BV. The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease. Curr Pharm Des 2008; 14(16): 1601-5.
190. Hoozemans JJ, Rozemuller JM, van Haastert ES, Veerhuis R, Eikelenboom P. Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology. Curr Pharm Des 2008; 14(14): 1419-27.
191. Ohlson S. Designing transient binding drugs: A new concept for drug discovery. Drug Discov Today 2008; 13(9-10): 433-9.